Orally administered cladribine displays efficacy in multiplesclerosis trial.
Yates
Darran
D
D000284:Administration, Oral; D001921:Brain / Q000187:drug effects / Q000473:pathology; D017338:Cladribine / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
D007166:Immunosuppressive Agents; D017338:Cladribine